title: Increase of bone mineral density with sodium fluoride in patients with Crohn's disease.
abstract: OBJECTIVE
  Low bone density with an increased risk of vertebral fractures is a frequent complication in inflammatory bowel disease. Since the aetiology of osteopathia in these patients is different compared to postmenopausal or steroid-induced osteoporosis, no treatment strategy is established. Supplementation of calcium and vitamin D has been shown to prevent further bone loss, but no data are available showing the anabolic effect of sodium fluoride in Crohn's disease.
  
  
  METHODS
  We carried out a one-year prospective clinical trial in 33 patients with chronic active Crohn's disease who were randomly assigned to receive either calcium (500 mg b.i.d.) and 1000 IU vitamin D3 only, or retarded-release sodium fluoride (25 mg t.i.d.) additionally. The diagnosis of Crohn's disease had been made at least two years ago, and all patients had received systemic high-dose steroid therapy during the previous year. Eleven of 15 patients who received calcium/vitamin D and 15 of 18 patients who additionally received sodium fluoride completed the study. The primary endpoint of the study was the increase of bone mineral density, measured by dual energy X-ray absorptiometry (DXA) after one year of treatment. Bone-specific alkaline phosphatase and osteocalcin were used as markers for bone turnover.
  
  
  RESULTS
  In the calcium/vitamin D only group, bone density was not significantly changed after one year of treatment, whereas in the calcium/vitamin D/fluoride group, bone density of the lumbar spine increased from -1.39+/-0.3 (Z-score, mean +/- SEM) to -0.65+/-0.3 (P<0.05) after one year of treatment. Increase of bone density was positively correlated to the osteoblastic markers bone-specific alkaline phosphatase (r = 0.53) and osteocalcin (r = 0.43).
  
  
  CONCLUSIONS
  Sodium fluoride in combination with vitamin D and calcium is an effective, well-tolerated and inexpensive treatment to increase lumbar bone density in patients with chronic active Crohn's disease and osteoporosis.
authors.affiliation: Department of Medicine I, University of Ulm, Germany.
authors.forename: C
authors.initials: C
authors.lastname: von Tirpitz
authors.forename: J
authors.initials: J
authors.lastname: Klaus
authors.forename: J
authors.initials: J
authors.lastname: Brückel
authors.forename: A
authors.initials: A
authors.lastname: Rieber
authors.forename: A
authors.initials: A
authors.lastname: Scholer
authors.forename: G
authors.initials: G
authors.lastname: Adler
authors.forename: B O
authors.initials: BO
authors.lastname: Böhm
authors.forename: M
authors.initials: M
authors.lastname: Reinshagen
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D002118:Calcium / Q000008:administration & dosage; D002762:Cholecalciferol / Q000008:administration & dosage; D003424:Crohn Disease / Q000150:complications*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D002762:Cholecalciferol; D012969:Sodium Fluoride; D002118:Calcium